In terms of volume, India is the world’s largest provider of generic pharmaceuticals, with a 20 per cent share of the global market. It also delivers around 60 per cent of the world’s vaccine supply. Antiretroviral medications (which are used in the fight against AIDS) are manufactured in India by pharmaceutical firms 80 per cent of the time, according to the WHO.
New and existing pharmaceutical businesses in India have reacted to the tremendous demand caused by the present pandemic by expanding their healthcare facilities. By 2023, it is predicted that global pharmaceutical sales will have surpassed USD 1.5 trillion. India is a prominent participant in the pharmaceutical sector on a worldwide scale. The country of India provides more than half of the worldwide market for immunizations. In contrast, the country of India supplies 40 per cent of the demand for generic medications in the United States.
According to projections, pharmaceutical spending in India would expand at an annual pace of 8-11 per cent between 2019 and 2023 and reach between 28 and 32 billion US dollars.
The top ten pharma companies in India are in the following:
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd is an Indian multinational pharmaceutical company that is ranked among the top 10 pharmaceutical companies in the world. The company manufactures and sells pharmaceutical formulations as well as active pharmaceutical ingredients (APIs) in India and the United States. The corporation is considered to be one of the most renowned and respectable pharmaceutical companies in India. India is a prominent multinational pharmaceutical firm with a global presence. Sun Pharmaceutical Industries was founded in the year 1983. Mr Dilip Shanghvi, the company’s founder and CEO, is also the company’s president and chief executive officer. The firm began selling drugs for the treatment of mental disorders. In addition, the firm now provides formulations in a variety of therapeutic, gastrointestinal, and diabetology areas of use. It comes under the top 10 pharmaceutical companies in India.
APIs such as etodolac, clorazepate, carbamazepine, and warfarin are also available from the firm. Anti-cancer medications, peptides, steroids, sex hormones, etc., are also provided. The company offers more than 2000 formulas, which also sells to other countries. Sun Pharma was named 2017’s Entrepreneur of the Year by the All-India Management Association (AIMA).
Dr Reddy’s Laboratories Ltd
An Indian pharmaceutical giant, Dr Reddy’s Laboratories, has a global presence. The firm manufactures and sells a wide range of medications domestically and internationally. More than 190 medications, 60 active pharmaceutical ingredients (APIs), biotechnology goods, critical care items, and diagnostic kits are available from this company. It comes under the top 10 pharmaceutical companies in India.
Manufacturing is carried out at seven locations around the country. In 1992, the corporation made its first foray into Russia and extended its activities. Dr Reddy’s Laboratories has consented to conduct final-stage clinical trials of Russia’s Sputnik V COVID-19 vaccine in India to combat the COVID-19 pandemic. Following the successful conclusion of clinical studies and regulatory approvals, they are expected to manufacture up to 100 million doses. Pharmaceuticals are manufactured and sold by Dr Reddy’s in India and abroad. Pharmaceutical ingredients (APIs) for drug manufacturing, diagnostic tests for critical care, and biotechnology products are all available from the firm.
As a supplier to Indian pharmaceutical companies, Dr Reddy’s first ventured into exporting to less-regulated countries. It didn’t have to invest in a manufacturing facility that had to be approved by a drug licensing organization like the U.S. Food and Drug Administration (FDA) (FDA). When these unregulated markets grew in size and profitability in the early 1990s, the business began concentrating on securing permission from drug regulators for its formulations and bulk drug production factories in more developed nations. They were able to enter regulated markets, including the US and Europe, due to this. According to the Brand Trust Report 2014, a survey done by Trust Research Advisory, a brand analytics organization, Dr Reddy Laboratories, was included among 1200 of India’s most trusted companies in 2014.
Divis Laboratories is a manufacturer of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical compounds, focusing on exportation. Divi Laboratories has two production facilities and is considered one of the country’s premier pharmaceutical enterprises. Because of its market capitalization, it has risen to the top of the list of pharmaceutical companies in India.
They have three production facilities as well as three research and development facilities. Divi’s Labs is one of the newest companies on the market, which allows it to be included in the top ten list of major pharmaceutical companies. The company exports the items to countries like the United States, Europe, Japan, South Africa, Australia, and the Philippines.
Divi’s Laboratories, formerly known as Divi’s Research Center, was founded in 1990. Initially, the firm focused on creating commercial techniques for producing active pharmaceutical ingredients (APIs) and intermediates. In 1994, Divi’s Research Centre changed its name to Divi’s Laboratories Limited to signify its intention to join the pharmaceutical active pharmaceutical ingredient (API) and intermediates production sector.
The next year, the business built its first manufacturing plant at Choutuppal, Telangana, completed in 1996. In 2002, the company’s second production plant, located near Visakhapatnam, began operations, becoming the company’s second manufacturing facility.
The firm went public with its initial public offering (IPO) on February 17, 2003. In 2010, the business opened a research centre in Hyderabad, where it has been operating since. Divis Laboratories is a pharmaceutical company specializing in the production of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical compounds, focusing on exports. Divi’s has been in business in Hyderabad, India, for over 29 years and has two production facilities. It is one of the country’s leading pharmaceutical enterprises headquartered in Hyderabad. To provide clients with world-class goods, 11,000 highly skilled workers across departments and 350 scientists at Divi’s collaborate.
Cipla is one of the world’s biggest pharmaceutical companies, specializing in high-quality generic pharmaceuticals. Patients and healthcare professionals throughout the globe have come to rely on the company. Products from the firm are available in a wide variety. There is a strong corporation presence in both the Indian and worldwide markets. The business serves more than 150 nations.
Because of the company’s international reputation and approvals from key global regulatory authorities for adhering to the highest quality standards, Healthcare experts and patients worldwide have a high degree of confidence in the company. A total of Rs. 16362 Cr. has been made by the company. On the list of India’s top 10 pharmaceutical firms, the company ranks fourth. This Indian pharmaceutical business specializes in the research and development of drugs for various ailments, including asthma, heart disease, arthritis, diabetes, obesity, and depression. It comes under India’s top pharma company.
By solidifying and increasing its footprint in India, South Africa, the United States, and other growing nations, the corporation has strengthened its worldwide emphasis. Bulk medication production facilities were allowed in 1985 by the US Food and Drug Administration (FDA). It was led by Yusuf Hamied, the founder’s son, a Cambridge-educated chemist, who delivered generic AIDS and other pharmaceuticals to underprivileged people in the developing globe.  Deferiprone, the world’s first oral iron chelator, was introduced by Cipla in 1995. It was less than $350 per patient per year when Cipla began offering HIV medications (antiretrovirals) in 2001.
Cipla purchased Cipla-Medpro, a South African firm, in 2013 and renamed it Cipla Medpro South Africa Limited. Cipla-Medpro was South Africa’s third-largest pharmaceutical firm at the time of the purchase and was a distribution partner for Cipla. Eleni Pharmaceuticals Ltd. was created in 2002 and renamed in 2013.
Founded in Pondicherry, India, in 1988-89, Aurobindo Pharma began operations with a single production plant producing Semi-Synthetic Penicillin. After going public in 1992, the firm has grown tremendously. Other therapeutic areas where the firm is active include cardiology, antiretrovirals, neurosciences, anti-biotics, gastroenterology, anti-diabetic drugs, and anti-allergy drugs. The company also manufactures semi-synthetic penicillin.
Currently, the firm sells its goods to more than 150 countries worldwide. Aurobindo Pharma is comprised of manufacturing and research & development facilities.
All of the items provided by this organization are both effective and cost-effective. These products are of excellent quality and have a high demand in the market today. It works as a marketing partner for multinational corporations such as AstraZeneca and Pfizer ltd. In 1995, Aurobindo Pharma became a publicly-traded company on the New York Stock Exchange. In the year 2014, Aurobindo purchases the company ACTAVIS. It carries out general activities in nations across Western Europe.
Aurobindo Pharma intends to broaden its product range by adding high-value items in cancer, hormones, biosimilars, and innovative drug delivery options such as depot injections, inhalers, patches, and films to its existing product line. Additionally, it has set its eyes on regional growth in new territories such as Poland, Italy, Spain, the Czech Republic, Portugal, and France, despite the fact that the generic medication industry in these nations is still in its early stages.
Generis Farmaceutica SA, a pharmaceutical company, based in Portugal, was acquired by Aurobindo Pharma from Magnum Capital Partners for a total price of €135 million in 2017. According to the company, it also bought four biosimilar pharmaceuticals from the Swiss company TL Biopharmaceutical AG.
It was announced today that Aurobindo Pharma Ltd. had reached a formal deal to acquire the Apotex operations in Poland, the Czech Republic, and the Netherlands, Spain, and Belgium. The agreement is subject to competition approvals for the transaction from the Dutch and Polish competition authorities, respectively. To support the continued expansion objectives of these companies, Apotex will engage in a transitional production and supply relationship with Aurobindo as part of the planned sale of the company.
In India, Torrent Pharma was a pioneer in introducing specialized marketing. When it comes to treating women’s health issues, including cardiovascular, central nervous system and gastrointestinal issues, they are leaders. There is a strong presence in diabetology, gynecology, pain management, and anti-infective medicine by the company. In India, the company pioneered the notion of specialty marketing and is now one of the leading players in the therapeutic segments of cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI) and women’s healthcare (WH) (WHC).
Diabetology, Pain Management, Gynecology, Oncology, and Anti-Infective Segments are additional strongholds for the company. Competitive advantage for Torrent Pharma comes from its world-class production facilities, superior R&D skills, vast local network, and a worldwide presence in over 40 countries. Torrent Pharma
They have world-class production facilities, cutting-edge R&D facilities, a wide domestic network, and a strong worldwide presence in more than 40 countries.
In 2013, the firm acquired Elder Pharma’s Indian company, in 2015, Zyg Pharma’s Dermaceutical business, in 2016 Glochem Industries’ API factory, in 2017 Unichem’s Indian branded business and it is Sikkim Plant acquired from Novartis. Its position in the Indian pharmaceutical market was strengthened by the acquisition of Elder Pharma’s Indian brand business in 2013, Dermaceutical business from Zyg Pharma in 2015, API plant from Glochem Industries in 2016, women’s healthcare brands from Novartis and Unichem’s Indian brand business and its Sikkim plant in 2017.
Similarly, in January 2018, Torrent purchased generic medicines and over-the-counter (OTC) firm Bio-Pharm, Inc. The company deals with a broad range of products, including those in the CNS, cardiovascular, diabetology, gastrointestinal, pain management, and anti-infective sectors, as well as other subspecialties. Several locations around the country are home to the company’s production facilities. The company has a global network of affiliates. Heumann GmbH, a subsidiary of Pfizer, was purchased by the business in 2005.
Branded and Generic Formulations, Biotechnology Things, APIs, etc., are only a few of Lupin’s products to its customers. India, Japan, Brazil, Mexico and the United States are the company’s production hubs. Non-Steroidal Anti-Inflammatory Pharmaceuticals, Cardiovascular, CNS, Gynaecology, Asthma, Paediatric, Diabetology, Gastrointestinal, and Anti-Infective drugs are sectors in which the firm has a significant presence.
Aside from Anti-TB and Cephalosporins, the firm has a worldwide leading position. The firm represents more than a hundred nations. As a leading pharmaceutical company, it provides high-quality yet affordable medicines for some of the world’s most chronic illnesses.
Anti-TB and Cephalosporins are also Lupin’s strongest areas of business. Lupin is a global pharmaceutical company with a presence in more than 100 countries and provides high-quality, cheap medications for some of the world’s most chronic ailments. Numerous countries in Asia, Africa, Europe, South America, South Africa and the Middle East are important markets for Lupin Limited. Lupin Pharmaceutical Inc. and Kyowa Pharmaceutical Industry Co. Ltd. are just a few Lupin Ltd.’s numerous subsidiaries.
Zydus Cadila Healthcare
This is a pioneer pharmaceutical firm, one of the oldest in India’s formulations industry, and has since become India’s most renowned producer.
As part of the company’s Innovation program, 1300 researchers from 19 locations around the country work on cutting-edge pharmaceutical products. NCEs, vaccines, biosimilars, and other specialized specialty technologies are all on the table for discussion as part of this project. In India, there are research centres for corporations in Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. They have research facilities in the United States and Brazil as well.
There is a considerable presence of the company’s worldwide operations in the regulated markets of the U.S., Europe, and South Africa and Latin America. In addition, it is present in 25 new markets throughout the globe.
This publicly traded firm is a subsidiary of Abbott Laboratories United States, headquartered in New York City. Among the treatments offered by the company are Women’s Health, Neurology, Thyroid, Gastroenterology, Anti-Infectives, Diabetes Treatment, Urology Treatment, Pain Management Treatment, Vitamins, and others. They have a factory in Verna, Goa, which makes high-quality and high-volume formulations. It is enlisted as the best top pharma company in India.
Medical device manufacturer Abbott India Laboratories is based in the United States. Pharmaceuticals, diagnostics, medical gadgets, and nutrition have all seen breakthroughs because of Abbott Laboratories.
Top-quality branded generics, generic medicines, APIs, and nutraceuticals are sold by Alkem Laboratories in India and more than 50 other nations. As one of India’s top 10 pharmaceutical companies for the last 15 years, the business has a comprehensive product portfolio of over 750 brands and a robust pan-India sales and distribution network.
Alkem Laboratories has been India’s top anti-infective firm for more than a decade. They are among the top pharmaceutical businesses in gastrointestinal, vitamins/minerals/nutrients, and pain treatment. The company has a broad range of over 750 products in all therapeutic areas and a well-established sales and distribution network in India. It is enlisted in the top ten pharma companies in India. For the last 15 years, the firm has consistently been one of India’s top 10 pharmaceutical companies in terms of domestic sales.
The Taloja facility of Alkem’s ANDA research and development was established in 2003. For the first time in the Indian pharmaceutical business, Alkem’s Taxim became the first anti-infective medicine with domestic sales exceeding a billion rupees. This year Alkem’s Clavam became the first Alkem medicine to reach the 2,000 million dollar barrier in domestic sales in India in 2014. Amlodipine was authorized in 2009 after the business submitted its first ANDA for the medicine in 2007. In the six months that concluded on September 30, 2015, Alkem has built a portfolio of 705 branded generic pharmaceuticals, 13 of which were among India’s top 300 most popular brands. With 19 in India and 2 in the United States, Alkem has 21 facilities. The FDA, TGA, and MHRA have authorized five of the facilities.
Read More: Best Garner